Amygdala-prefrontal disconnection in borderline personality disorder.
Abnormal fronto-amygdala circuitry has been implicated in impulsive aggression, a core symptom of borderline personality disorder (BPD). We examined relative glucose metabolic rate (rGMR) at rest and after m-CPP (meta-chloropiperazine) with (18)fluorodeoxyglucose (FDG) with positron emission tomography (PET) in 26 impulsive aggressive (IED)-BPD patients and 24 controls. Brain edges/amygdala were visually traced on MRI scans co-registered to PET scans; rGMR was obtained for ventral and dorsal regions of the amygdala and Brodmann areas within the prefrontal cortex (PFC). Correlation coefficients were calculated between rGMR for dorsal/ventral amygdala regions and PFC. Additionally, amygdala volumes and rGMR were examined in BPD and controls. Correlations PFC/amygdala Placebo: Controls showed significant positive correlations between right orbitofrontal (OFC) and ventral, but not dorsal, amygdala. Patients showed only weak correlations between amygdala and the anterior PFC, with no distinction between dorsal and ventral amygdala. Correlations PFC/amygdala: m-CPP response: Controls showed positive correlations between OFC and amygdala regions, whereas patients showed positive correlations between dorsolateral PFC and amygdala. Group differences between interregional correlational matrices were highly significant. Amygdala volume/metabolism: No group differences were found for amygdala volume, or metabolism in the placebo condition or in response to meta-chloropiperazine (m-CPP). We demonstrated a tight coupling of metabolic activity between right OFC and ventral amygdala in healthy subjects with dorsoventral differences in amygdala circuitry, not present in IED-BPD. We demonstrated no significant differences in amygdala volumes or metabolism between BPD patients and controls.
New
Antonia S
AS
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA. antonia.new@mssm.edu
Hazlett
Erin A
EA
Buchsbaum
Monte S
MS
Goodman
Marianne
M
Mitelman
Serge A
SA
Newmark
Randall
R
Trisdorfer
Roanna
R
Haznedar
M Mehmet
MM
Koenigsberg
Harold W
HW
Flory
Janine
J
Siever
Larry J
LJ
D000328:Adult; D000374:Aggression / Q000502:physiology; D000679:Amygdala / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D001284:Atrophy / Q000000981:diagnostic imaging / Q000473:pathology / Q000503:physiopathology; D001883:Borderline Personality Disorder / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology*; D004644:Emotions / Q000502:physiology; D004734:Energy Metabolism / Q000502:physiology; D005260:Female; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007175:Impulsive Behavior / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009434:Neural Pathways / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology*; D010879:Piperazines; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D017397:Prefrontal Cortex / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology*; D017366:Serotonin Receptor Agonists
D010879:Piperazines; D017366:Serotonin Receptor Agonists; D019788:Fluorodeoxyglucose F18; D005947:Glucose; C015068:1-(3-chlorophenyl)piperazine